Cipla’s healthy growth outlook with robust revenue and profit expectations has earned the stock a rating upgrade from Motilal Oswal. The brokerage has upgraded Cipla stock to ‘buy’ with a target price of Rs 1,420. This implies about 15 percent upside from Monday’s closing price of Rs 1244.
Motilal Oswal foresees a 16 percent PAT CAGR for Cipla over FY 2023-25, and expects a 15 percent sales CAGR to reach $1 billion through FY25. The drugmaker’s sales growth across the major geographies US, India and South Africa will be powered by niche launches, superior execution and higher offtake in complex generics, prescription drugs and private/ OTC market.
Cipla’s US sales remain resilient amid price erosion
Cipla has been a frontrunner among pharma companies under MOFSL’s coverage during FY13-23 as it recorded a US sales CAGR (Compounded Annual Growth Rate) of 21.6 percent to reach $733 million by the end of the decade.